Procyte begins UK trial of wound healing agent
This article was originally published in Clinica
Procyte has been cleared by the UK Medicines Control Agency to begin a Phase II clinical trial of its wound healing agent, Iamin, in the UK. Iamin is a topical prezatide copper acetate gel for the treatment of chronic and acute wounds, including venous stasis ulcers, pressure sores, diabetic ulcers and postoperative surgical wounds. The trial will be conducted at the Oxford Wound Healing Institute in Churchill Hospital which is part of the Oxford Radcliffe NHS Trust.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.